<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414778</url>
  </required_header>
  <id_info>
    <org_study_id>CLHT344A2101</org_study_id>
    <nct_id>NCT00414778</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects</brief_title>
  <official_title>A Single-center, Open-label, Single and Multiple Oral Dose Study to Assess Safety and Pharmacokinetics of LHT344 in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetics of a single and multiple&#xD;
      dose of LHT344 in 12 Chinese healthy subjects.&#xD;
&#xD;
      This study is not recruiting subjects in the United States.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of single and repeat daily oral dose of LHT344 in Chinese healthy subjects</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of single and repeat daily oral dose of LHT344 in Chinese healthy subjects</measure>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHT344</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy, non-smoking, male or female subjects age 18 to 45 years of age&#xD;
&#xD;
          -  In good health as confirmed by past medical history, physical examination,&#xD;
             electrocardiogram, laboratory tests and urinalysis on the screening and baseline&#xD;
             evaluation&#xD;
&#xD;
          -  Body mass index within the range of 19 to 24 kg/m2 and weigh at least 50 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter&#xD;
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to&#xD;
             dosing. Paracetamol is acceptable.&#xD;
&#xD;
          -  Participation in any clinical investigation within 3 months prior to dosing.&#xD;
&#xD;
          -  Donation or loss of 400 mL or more of blood within 12 weeks prior to first dosing&#xD;
             required by local regulation.&#xD;
&#xD;
          -  Significant illness within 2 weeks prior to dosing.&#xD;
&#xD;
          -  A past personal or close family medical history of clinically significant cardiac&#xD;
             abnormalities such as a myocardial infarction, angina, arterial fibrillation,&#xD;
             arrhythmia or hypertension.&#xD;
&#xD;
          -  History of&#xD;
&#xD;
          -  fainting, low blood pressure upon standing, irregular heart beats&#xD;
&#xD;
          -  acute or chronic bronchospastic disease (including asthma and chronic obstructive&#xD;
             pulmonary disease, treated or not treated).&#xD;
&#xD;
          -  clinically significant drug allergy, history or presence of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis)&#xD;
&#xD;
          -  known hypersensitivity to the study drug or similar drugs&#xD;
&#xD;
          -  surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs or may jeopardize the subject&#xD;
             participation in the study&#xD;
&#xD;
          -  immunodeficiency diseases, including a positive HIV (ELISA and Western blot) test&#xD;
             result.&#xD;
&#xD;
          -  positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.&#xD;
&#xD;
          -  drug or alcohol abuse within the 12 months prior to study participation&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>December 21, 2006</study_first_submitted>
  <study_first_submitted_qc>December 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2006</study_first_posted>
  <last_update_submitted>January 12, 2011</last_update_submitted>
  <last_update_submitted_qc>January 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2011</last_update_posted>
  <keyword>Safety, pharmacokinetics, oral, single dose, multiple dose, LHT344, Chinese, healthy subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

